Last reviewed · How we verify
AFM 13
AFM 13 is a tetravalent bispecific antibody construct that targets CD30 on tumor cells and CD16A on natural killer (NK) cells, enhancing NK cell-mediated cytotoxicity against CD30-positive tumors.
AFM 13 is a tetravalent bispecific antibody construct that targets CD30 on tumor cells and CD16A on natural killer (NK) cells, enhancing NK cell-mediated cytotoxicity against CD30-positive tumors. Used for Hodgkin lymphoma, anaplastic large cell lymphoma.
At a glance
| Generic name | AFM 13 |
|---|---|
| Sponsor | Affimed GmbH |
| Drug class | bispecific antibody |
| Target | CD30, CD16A |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
AFM 13 binds to CD30 on the surface of tumor cells and CD16A on NK cells, leading to the activation and redirection of NK cells to specifically target and kill CD30-positive tumor cells, thereby enhancing the immune response against these malignancies.
Approved indications
- Hodgkin lymphoma
- anaplastic large cell lymphoma
Common side effects
- Cytokine release syndrome
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AFM 13 CI brief — competitive landscape report
- AFM 13 updates RSS · CI watch RSS
- Affimed GmbH portfolio CI